title: [Protection and mechanisms of salvianolic-acid B on experimental renal interstitial fibrosis in rats].
abstract: OBJECTIVE
  To investigate the effect and mechanism of salvianolic acid B (SA-B) on renal interstitial fibrosis in rats induced by unilateral ureteral obstruction (UUO).
  
  
  METHODS
  18 male SD rats were randomly divided into 3 groups, 6 in each group. After the models were established, the rats were treated with SA-B for 2 weeks. Then their renal pathology were examined by hight microscope and electron microscopy Protein expression levels of alpha-smooth muscle actin (alpha-SMA) and E-cadherin (E-cad) in the obstructed kidney were analyzed by Western blot and Biochemistry assay.
  
  
  RESULTS
  Pathological examination of the kidney in model group showed tubules lumen widened and many inflammatory cells infiltrated, a part of renal tubule expanded and part of them atrophied. The tubular epithelial cells were karyorrhexis or karyolysis, some tubulars were atrophy. The protein expression of alpha-SMA were significantly up-regulated (P < 0.01) and E-cad were significantly down-regulated (P < 0.01) in the model group. After intervention with SA-B, the renal pathological status in the treatment group was significantly improved, the expression of alpha-SMA were significantly down-regulated (P < 0.05), but E-cad only a little up-regulated (P > 0.05).
  
  
  CONCLUSIONS
  SA-B could antagonize renal interstitial fibrosis mainly by maintaining epithelial phenotype, inhibiting the protein of alpha-SMA which is the principal effect cells that are responsible for the progressive kidney fibrosis.
authors: Nursing College, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China. haiying2010@hotmail.com
authors: Hai-Ying
authors: HY
authors: Lu
authors: Juan
authors: J
authors: Zhou
authors: Min
authors: M
authors: Lu
authors: Yu-Min
authors: YM
authors: Liu
authors: Fei
authors: F
authors: Wang
authors: Min
authors: M
authors: Lin
authors: Yue
authors: Y
authors: Zhang
mesh_terms: D000199:Actins / Q000378:metabolism*; D000818:Animals; D001572:Benzofurans / Q000494:pharmacology* / Q000627:therapeutic use; D015153:Blotting, Western; D015820:Cadherins / Q000378:metabolism*; D004195:Disease Models, Animal; D005355:Fibrosis / Q000188:drug therapy / Q000473:pathology; D007150:Immunohistochemistry; D007668:Kidney / Q000378:metabolism / Q000473:pathology*; D007674:Kidney Diseases / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D007684:Kidney Tubules / Q000378:metabolism / Q000473:pathology; D008297:Male; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D014517:Ureteral Obstruction / Q000150:complications; D053630:Depsides
chemical_list: D000199:Actins; D001572:Benzofurans; D015820:Cadherins; C076944:salvianolic acid B; D053630:Depsides